360Dx

360Dx is a publication from GenomeWeb, an independent news source located in New York. Since its inception in 1997, GenomeWeb has been dedicated to supporting the worldwide community of scientists, tech experts, and leaders involved in creating and utilizing cutting-edge tools for molecular biology research and diagnostics. GenomeWeb operates as a division of Crain Communications.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1271048

United States

#536299

Health/Biotechnology and Pharmaceuticals

#516

Traffic sources

Monthly visitors

Articles

ASCO: Razor Genomics Test Shows Promise for Chemotherapy Selection in High-Risk Lung Cancer Patients

6 days ago | 360dx.com | Kelsy Ketchum

CHICAGO – In an abstract presented at the American Society of Clinical Oncology's annual meeting on Saturday, researchers demonstrated that Razor Genomics' RiskReveal 14-gene assay could help clinicians determine which patients with early-stage non-squamous non-small cell lung cancer should undergo adjuvant chemotherapy after surgery.
OncoHost Developing NeutroFlow Test for Guiding Cancer Therapy Selection

1 week ago | 360dx.com | Justin Petrone

NEW YORK – OncoHost, an Israeli biotechnology company, is working with three European medical centers to produce a new flow cytometry test to predict patient response to immunotherapies for five cancer indications, according to Michal Harel, OncoHost's vice president of translational medicine.
Alzheimer's Field Grappling With Risks, Benefits of Blood Testing in Primary Care

1 week ago | 360dx.com | Adam Bonislawski

NEW YORK – In May, the US Food and Drug Administration (FDA) issued the first 510(k) clearance of a blood-based test for Alzheimer's disease, a development that is likely to drive broader reimbursement and use of such products.
Agilent Technologies Looks to Supply Chain, Pricing, Restructuring to Mitigate Tariff Effects

1 week ago | 360dx.com | Greg Cima

NEW YORK – Agilent Technologies has been making changes to its supply chain, adjusting its pricing, and applying an ongoing restructuring program to mitigate the effects of US tariffs and retaliatory tariffs.
Japan's Eiken Chemical Aims to Transform Business, Expand Overseas Clinical Diagnostics Sales

2 weeks ago | 360dx.com | Madeleine Johnson

NEW YORK – Japan's Eiken Chemical, perhaps best known in the molecular biology space as the developer of the widely used loop-mediated isothemal nucleic acid amplification technology, has overhauled its executive team and revamped its mid- and long-term business strategies.
New Validation Data Shows Promise for AOA Dx Ovarian Cancer Early Detection Test

2 weeks ago | 360dx.com | Kelsy Ketchum

NEW YORK – Cancer diagnostic firm AOA Dx recently presented new data on its ovarian cancer test that shows its potential promise for detecting the disease at earlier stages. According to CEO Oriana Papin-Zoghbi, the multiomic assay, Akrivis, investigates lipids and proteins and relies on liquid chromatography-mass spectrometry, standard immunoassay, and machine learning to differentiate between ovarian cancer and other diseases.
Bio-Rad Laboratories Alerts Customers to Tariff Surcharges

2 weeks ago | 360dx.com | Madeleine Johnson

NEW YORK – Executives from Bio-Rad Laboratories said at an investment conference on Wednesday afternoon that while US tariff policy is seemingly changing day by day, the firm expects to see approximately $40 million in tariff-related revenue headwinds this year. On Monday, the firm also alerted its customers in an email to forthcoming tariff surcharges.
Institut Pasteur-Led Effort Aims to Deliver Lateral Flow Test for Combating Malaria

2 weeks ago | 360dx.com | Justin Petrone

NEW YORK – A team led by investigators at Institut Pasteur has commenced work on a new lateral flow assay that could be used to detect the presence of the malaria-causing parasite Plasmodium vivax in hard to diagnose, asymptomatic individuals. The project, called PvSeroRDT (short for P. vivax Sero (as in blood) RDT, rapid diagnostic test), received €4 million ($4.5 million) from the EU earlier this year and will run through 2030.
Optimism About New Tools, Capabilities Pump up Investments in Digital Pathology

2 weeks ago | 360dx.com | Greg Cima

NEW YORK – With new capabilities in digital pathology hardware and its analytical tools, investor enthusiasm in the field is quickly rising, according to industry observers.
Lab Stakeholders Decry Trump Administration's Decision to Terminate CLIAC

2 weeks ago | 360dx.com | Adam Bonislawski

NEW YORK – With its recent decision to discontinue the Clinical Laboratory Improvement Advisory Committee (CLIAC), the US Department of Health and Human Services (HHS) has shut down one of the laboratory industry's main conduits for providing the agency feedback on the functioning of the CLIA program.